Want to see JP:4890 full AI Analyst Report?
Tsubota Laboratory Incorporated (4890) AI Stock Analysis
Tsubota Laboratory Incorporated
(TSE/TYO:4890)
The overall score is critically low, driven primarily by a severe deterioration in financial performance, including collapsing revenue, large net losses, and persistent cash burn. Technicals confirm a sustained downtrend with bearish momentum, and the negative P/E ratio offers no valuation support. The company's low debt is the only minor positive, but it is insufficient to offset the fundamental and market-based risks.
Tsubota Laboratory Incorporated (4890) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 6.27B
- Dividend Yield
- ―
- Average Volume (3M)
- 40.76K
- Price to Earnings (P/E)
- -9.0
- Beta (1Y)
- 0.27
- Revenue Growth
- -71.21%
- EPS Growth
- -485.42%
- Country
- Japan
- Employees
- 22
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Specialty Business Services
Tsubota Laboratory Incorporated Business Overview & Revenue Model
Company Description
Operating from Tokyo, Japan since its establishment in 2012, Tsubota Laboratory Incorporated is dedicated to the research and development of pharmaceutical products and medical devices, specifically targeting the treatment of myopia, dry eyes, and pr...
How the Company Makes Money
The company primarily makes money by commercializing ophthalmology-related offerings, which typically includes monetization from product and/or service sales tied to eye-care solutions and potentially revenues associated with research and development...
Tsubota Laboratory Incorporated Financial Statement Overview
Summary
Financial health is precarious. The income statement shows an 85% revenue collapse and a -381% net margin in 2026. Cash flow is deeply negative for three consecutive years, burning ¥577.8M in operations. The balance sheet is eroding, with equity halving, though low debt (D/E 0.08) provides a minimal cushion. Overall, severe losses and cash burn dominate.
Income Statement
20Very NegativeBalance Sheet
45NeutralCash Flow
15Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 390.58M | 200.02M | 1.36B | 673.53M | 954.69M | 640.92M |
| Gross Profit | 148.27M | 131.57M | 1.15B | -9.48M | 686.83M | 528.76M |
| EBITDA | -720.42M | -765.24M | 262.46M | -609.24M | 206.22M | 173.87M |
| Net Income | -693.63M | -761.82M | 205.77M | -641.32M | 90.18M | 153.32M |
Balance Sheet | ||||||
| Total Assets | 1.31B | 1.32B | 2.50B | 2.30B | 2.67B | 1.62B |
| Cash, Cash Equivalents and Short-Term Investments | 699.26M | 969.85M | 1.54B | 1.88B | 2.16B | 1.17B |
| Total Debt | 63.64M | 69.21M | 90.38M | 116.90M | 139.34M | 223.82M |
| Total Liabilities | 578.57M | 454.92M | 915.85M | 927.93M | 722.59M | 873.44M |
| Stockholders Equity | 733.83M | 863.86M | 1.59B | 1.37B | 1.95B | 744.35M |
Cash Flow | ||||||
| Free Cash Flow | 0 | -586.61M | -331.75M | -313.35M | -15.27M | 582.69M |
| Operating Cash Flow | 0 | -577.83M | -317.75M | -301.35M | 28.49M | 654.91M |
| Investing Cash Flow | 0 | -8.41M | -14.55M | -12.00M | -54.03M | -72.23M |
| Financing Cash Flow | 0 | 17.23M | -12.25M | 35.74M | 1.01B | -18.53M |
Tsubota Laboratory Incorporated Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4890, the sentiment is Negative. The current price of 238.00 is below the 20-day moving average (MA) of 255.45, below the 50-day MA of 267.04, and below the 200-day MA of 278.55, indicating a bearish trend. The MACD of -4.35 indicates Positive momentum. The RSI at 38.53 is Neutral, neither overbought nor oversold. The STOCH value of 16.98 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4890.
Tsubota Laboratory Incorporated Peers Comparison
Overall Rating
JP:764969Neutral
JP:998969Neutral
JP:334959.9Neutral
JP:354956Neutral
JP:339154Neutral- JP:489038Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:7649 | 69Neutral | JPY 506.97B | 16.12 | 9.94% | 1.34% | 8.97% | -29.54% |
| JP:9989 | 69Neutral | JPY 422.80B | 13.44 | 11.15% | 3.65% | 4.32% | 0.18% |
| JP:3349 | 60Neutral | JPY 480.15B | 14.88 | ― | 1.36% | 8.99% | 3.61% |
| JP:3549 | 56Neutral | JPY 418.12B | 21.94 | ― | 0.34% | 12.54% | 15.87% |
| JP:3391 | 54Neutral | JPY 1.01T | 17.51 | 7.13% | 2.10% | ― | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JP:4890 | 38Underperform | JPY 6.31B | -9.03 | ― | ― | -71.21% | -485.42% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4890 | Tsubota Laboratory Incorporated | 243.00 | -84.00 | -25.69% | |
| JP:9989 | Sundrug Co | 3616.00 | -399.89 | -9.96% | |
| JP:7649 | Sugi Holdings Co | 1304.50 | -340.92 | -20.72% | |
| JP:3391 | TSURUHA Holdings | 2236.00 | -391.62 | -14.90% | |
| JP:3349 | COSMOS Pharmaceutical Corporation | 6032.00 | -789.24 | -11.57% | |
| JP:3549 | KUSURI NO AOKI HOLDINGS CO.,LTD. | 4373.00 | 523.54 | 13.60% |
Tsubota Laboratory Incorporated Corporate Events
Tsubota Laboratory Narrows Quarterly Loss as Revenue Surges and Eyes Full-Year Profit
Tsubota Laboratory reported a sharp increase in first-quarter revenue to ¥215 million, up more than eightfold year on year, while still posting a net loss of ¥134 million, which narrowed from the prior-year period. The company’s equit...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 25, 2026